Ochratoxin B

Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos^{[1][2][3][4][5][6]}. In Vitro:Ochratoxin B (1-25 µg/mL) causes pronounced inhibition of HepG2 cell division^[1].
Ochratoxin B (96 h) causes craniofacial malformations in Xenopus laevis embryos with less potency than Ochratoxin A^[2].
Ochratoxin B (0.001-100 mM; 24-96 h) shows different cytotoxicity levels in primary porcine (PKC), rat (RPTC), human renal proximal epithelial cells (HKC) and porcine renal cell line (LLC-PK1)^[3].
Ochratoxin B (2.5-25 μM) at lower concentrations (2.5 and 5 μM) reduces, and at higher subtoxic concentrations (25 μM) increases, Ochratoxin A-mediated toxicity in 3D MDCK cells^[4].
In Vivo:Ochratoxin B (single dose of 10 mg/kg bw or repeated doses of 2 mg/kg bw; p.o.; single dose or 5 days/week, 2 weeks) shows no significant adverse effects in rats^[5].
Ochratoxin B (4 mg/kg; i.p.) considerably reduces the toxic effects of Ochratoxin A when given together with Ochratoxin A in rats^[6].